Immatics (IMTX) Fundamentals 2026 — Revenue Analysis | SniperIQ
Immatics (IMTX) is a DE-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Immatics's market cap?
Immatics (IMTX) has a market capitalization of approximately
What is Immatics's P/E ratio?
Immatics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Immatics?
Immatics runs a net profit margin of -574.9%, a gross margin of 100.0%, and an operating margin of -570.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Immatics generate?
Immatics reported revenue of €48M for fiscal year 2025, with net income of -€196M and earnings per share (EPS) of -1.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Immatics pay a dividend?
Immatics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Immatics financially healthy?
Immatics carries a debt-to-equity ratio of 0.03x and a current ratio of 8.78x, with a market beta of 1.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Immatics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Immatics (IMTX) the key facts are: market cap
Track Immatics's full fundamentals live
Get Immatics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.